Response Genetics (Response Genetics) Margin of Safety % (DCF Dividends Based) : N/A (As of Jun. 20, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Response Genetics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Response Genetics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Response Genetics's Margin of Safety % (DCF Dividends Based)

For the Diagnostics & Research subindustry, Response Genetics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Response Genetics's Margin of Safety % (DCF Dividends Based) Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Response Genetics's Margin of Safety % (DCF Dividends Based) falls into.

Response Genetics Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Response Genetics's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Response Genetics (Response Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070

Website

http://www.responsegenetics.com

Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.

Executives

Roberto Mignone	10 percent owner	C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber	director	15 TROTTERS LANE, MONROE CT 06468
Sam Chawla	director	1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris	officer: Vice President and CFO	345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya	director	C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna	director, officer: Chief Executive Officer	4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M	10 percent owner	C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc	10 percent owner	90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics (Response Genetics) Headlines

From GuruFocus

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor • 12-14-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-22-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009

Response Genetics Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-14-2010